Asymmetric dimethylarginine: A novel cardiovascular risk factor in end-stage renal disease

M. Yusuf Alsagaff, M. Thaha, M. Aminuddin, R. M. Yogiantoro, M. Yogiantoro, Y. Tomino

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Objective: This cross-sectional study explored the association between carotid intima-media thickness (CIMT) and the oxidative stress markers asymmetric dimethylarginine (ADMA) and homocysteine in patients with end-stage renal disease who were on haemodialysis. Methods: A total of 30 patients undergoing chronic haemodialysis treatment were recruited to this study. Homocysteine and ADMA levels were determined using a fluorescence polarization immunoassay and an enzyme-linked immunosorbent assay, respectively. CIMT was measured as a marker of atherosclerosis using highresolution ultrasonography and was performed after haemodialysis. Results: Significant positive correlations were found between CIMT and ADMA, and CIMT and duration of haemodialysis. Linear regression analysis showed that ADMA level and age were significant independent determinants of CIMT, whereas homocysteine was not. Conclusion: The relationship demonstrated between plasma ADMA and carotid artery thickening suggests that ADMA may be a novel marker of atherosclerosis in patients on haemodialysis.

Original languageEnglish
Pages (from-to)340-349
Number of pages10
JournalJournal of International Medical Research
Issue number1
Publication statusPublished - Feb 2012


  • Arteriosclerosis
  • Asymmetric dimethylarginine (ADMA)
  • Carotid intima-media thickness
  • End-stage renal disease


Dive into the research topics of 'Asymmetric dimethylarginine: A novel cardiovascular risk factor in end-stage renal disease'. Together they form a unique fingerprint.

Cite this